Biolargo, Inc.
BLGO- Exchange
- OTC
- Industry
- Chemicals & Allied Products
- SEC CIK
- 0000880242
No open-market purchases or sales by Biolargo, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $13.4K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Biolargo, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Biolargo, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Code Kenneth Reay | Chief Science Officer | 26,408,319 | Jul 7, 2026 | 4 |
| Calvert Dennis P | President | 11,058,108 | Jul 2, 2026 | 3 |
| Strommen Jack B. | Director | – | Jul 2, 2026 | 4 |
| Park Linda | Director | – | Jul 2, 2026 | 4 |
| Bray Christina Elaine | Director | – | Jul 2, 2026 | 4 |
| Marshall Dennis E | Director | – | Jul 2, 2026 | 5 |
| Dargan Charles K | Chief Financial Officer | – | Feb 3, 2026 | 1 |
| Roberts Kent Charles II | Director | – | Oct 5, 2022 | 0 |
| Runyan John S. | Director | – | Oct 5, 2022 | 0 |
| Provenzano Joseph L | Secretary | – | Apr 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.